CLNN
Clene Inc.
There isn't enough reported data to score CLNN yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CLNN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CLNN's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CLNN PE Valuation
CLNN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CLNN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CLNN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CLNN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.66 | +$1.01 |
| Q2 2026 | -$3.56 | +$0.48 |
| Q1 2026 | -$3.26 | +$1.06 |
| Q4 2025 | -$2.66 | +$3.37 |
| Q3 2025 | -$3.67 | +$2.35 |
| Q2 2025 | -$4.04 | +$1.16 |
| Q1 2025 | -$4.32 | +$5.62 |
| Q4 2024 | -$6.03 | +$5.11 |
CLNN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CLNN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56K | +273% |
| Q2 2026 | $90K | +233% |
| Q1 2026 | $15K | -81% |
| Q4 2025 | $77K | -15% |
| Q3 2025 | $15K | -83% |
| Q2 2025 | $27K | -70% |
| Q1 2025 | $81K | +11% |
| Q4 2024 | $91K | -46% |
CLNN's revenue is recovering but still below its 2023 peak: $56,000 last quarter, up 273% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11334% | +26319 points |
| Q2 2026 | -5941% | +15777 points |
| Q1 2026 | -13740% | -8708 points |
| Q4 2025 | -9734% | -223 points |
| Q3 2025 | -37653% | -28671 points |
| Q2 2025 | -21719% | -13597 points |
| Q1 2025 | -5032% | +7615 points |
| Q4 2024 | -9511% | -3670 points |
CLNN's operating margin was −11334% last quarter, up 26319 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CLNN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CLNN on profitability, with a higher operating margin.
CLNN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.7M | -$665K |
| Q1 2026 | -$4.5M | +$483K |
| Q4 2025 | -$4.8M | +$39K |
| Q3 2025 | -$4M | -$979K |
| Q2 2025 | -$4.7M | +$1.6M |
| Q1 2025 | -$5M | +$2.1M |
| Q4 2024 | -$4.9M | +$2.3M |
| Q3 2024 | -$3M | +$3.8M |
CLNN has the stronger cash trend. Its trailing FCF is up 38% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
CLNN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +2.3M shares |
| 1 year | +43% | +4.4M shares |
| 3 years | +128% | +8.2M shares |
| 5 years | +319% | +11.2M shares |
| Available history | +323% | +11.2M shares |
CLNN has 15M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CLNN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CLNN Net Leverage
CLNN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CLNN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 36.9 | Neutral |
CLNN's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CLNN PE vs Healthcare Sector
| Metric | CLNN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CLNN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CLNN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.88 | 3.1% above |
| 20 week MA | $4.47 | 11% below |
| 50 week MA | $5.23 | 24% below |
| 100 week MA | $5.19 | 23% below |
| 200 week MA | $8.40 | 52% below |
CLNN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CLNN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.2 | $229.0 | +9.5% |
| 2021 | $229.0 | $87.4 | -62% |
| 2022 | $87.4 | $20.2 | -77% |
| 2023 | $20.2 | $5.93 | -71% |
| 2024 | $5.93 | $4.99 | -16% |
| 2025 | $4.99 | $6.25 | +25% |
| 2026 YTD | $6.25 | $4.00 | -36% |
CLNN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.